ISPOR 2022

Research Presentations

Get in Touch

Ontada

May 15-18 Washington, DC Booth 217

Community oncology serves a more diverse, more inclusive patient journey. Inherent in that service is the need to address Social Determinants of Health (SDOH), which present both challenges and opportunities in the equity and advancement of cancer care. As a catalyst of advancement, we are actively addressing these challenges head on –integrating experience, intelligence, empathy and hope into next-generation oncology innovation.

Lack of Standardization in Quantitative Evaluations of the Efficacy-Effectiveness Gap (EEG) for Cancer Therapies: A Targeted Literature Review (TLR)

MONDAY

A Proposed Framework for Evaluating Continuity of Data Coverage in Electronic Health Record and Administrative Claims Data in Real-World Evidence (RWE) Studies

May 16, 2022

TUESDAY

Integrating Data from Disparate Sources to Create a Comprehensive Patient Journey: A Case Study in Prostate Cancer

HER2 and Other Biomarker Testing Patterns Among Patients with Advanced Gastric Cancer (GC) or Gastric Esophageal Junction Cancer (GEJC)

May 17, 2022

HOPE Studies

Ontada at a glance

Publications

Learn More

Let's Connect.

Whether you’re focused on capturing unique data to power provider engagement or are looking to real-world evidence to catalyze groundbreaking research, we can help you meet your goals and achieve the best patient outcomes.

FORM

Get in Touch

Ontada

Qiqiang (John) Bian, Ph.D.

Learn more >

E. Susan Amirian, M.S.P.H., Ph.D.

Learn more >

Joseph Dye, Ph.D., R.PH.

Learn more >

Lisa Herms, M.Sc.

Learn more >

Pooja Chopra, M.S.

Learn more >

Thomas Wilson, Ph.D., Dr.P.H.

Learn More

Research Presentations

ISPOR 2022

Our Featured Researchers

FDA Public Comment Letters

Learn More

Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products (FDA-2021-D-1214)

Data Standards for Drug and Biological Submissions Containing Real- World-Data: Guidance for Industry (FDA-2021-D-0548)

Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry (FDA-2021-D-1146)

Re: Real-World Data: Assessing Electronic Health Records (EHRs) and Medical Claims Data to Support Regulatory Decision-Making for Drugs and Biological Products (FDA-2020-D-2307)

Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products (FDA-2021-D-1214)

Data Standards for Drug and Biological Submissions Containing Real- World-Data: Guidance for Industry (FDA-2021-D-0548)

Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry (FDA-2021-D-1146)

Re: Real-World Data: Assessing Electronic Health Records (EHRs) and Medical Claims Data to Support Regulatory Decision-Making for Drugs and Biological Products (FDA-2020-D-2307)

E. Susan Amirian, M.S.P.H, Ph.D., Ontada

ePoster

at 12.15 - 1.15 EDT

Poster

at 12.15 - 1.15 EDT

Qiqiang (John) Bian, Ph.D., Ontada

Application of Medication History for Comorbidity Assessment in Cancer

Poster

at 5.30 - 6.30 EDT

Joseph Dye, Ph.D, R.PH., Ontada

Poster

at 12.15 - 1.15 EDT

Pooja Chopra, M.S., Ontada

Poster

at 5.30 - 6.30 EDT

Lisa Herms, M.Sc., Ontada

Feasibility of Using Oncology Specific Electronic Health Records (EHR) Data to Emulate Clinical Trial Inclusion and Exclusion Criteria

Podium

at 4.30 - 5.30 EDT

Thomas Wilson, Ph.D., Dr.P.H., Ontada

SUN

MAY

2022

HOPE Studies

Learn More

Ontada at a glance

Learn More

Publications

Learn More

Research Presentation

Get in Touch

Ontada

HOPE Studies

Learn more >

Kat Aguilar, M.P.H.

Frequency of and Testing Patterns for Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (DMMR) among Solid Tumors in a US Community Oncology Setting

Anupama Vasudevan, Ph.D., Ontada

ePoster

at 9.45 - 1.15 EDT

MON

MAY

2022

MON

MAY

2022

MON

MAY

2022

Poster

TBD

Frequency of and Testing Patterns for Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (DMMR) among Solid Tumors in a US Community Oncology Setting

Anupama Vasudevan, Ontada

Thomas Wilson, Ph.D., Dr.P.H. Sr. Oncology RWE Research Director

Expertise An epidemiologist specializing in observational and comparative effectiveness research, Dr. Wilson has a special interest in the role social, economic, and mental/behavioral factors play in health, access to care, treatment and outcomes. Education & Experience Dr. Wilson holds a DrPH in epidemiology from UCLA and a PhD in biological history from BGSU. He was an NIH post-doctoral fellow, a Fulbright award winner, and has held research faculty positions at UC Berkeley and Columbia University. In a previous roles, Dr. Wilson served as the epidemiology director at Anthem Blue Cross Blue Shield and other organizations.

E. Susan Amirian, M.S.P.H., Ph.D. Sr. RWE Research Director

Expertise An epidemiologist with over 15 years of experience leading oncology-focused observational research studies, Dr. Amirian’s expertise is in the use of advanced methods, complex study designs, and molecular data. Education & Experience Dr. Amirian holds a PhD in epidemiology with a minor in biostatistics from the University of Texas. She completed a postdoctoral fellowship at Baylor College of Medicine, where she later served as faculty. Much of her research has involved optimizing use of data from multi-site consortia and existing data sources to generate high-quality evidence and insights in cancer etiology, prognostic factors, and treatment effects.

Joseph Dye, Ph.D., R.PH. Sr. RWE Research Director

Expertise An HEOR and healthcare professional with over 25 years of experience, Dr. Dye has expertise impacting population health through collaborative partnerships and evidence-based decision making across multiple healthcare sectors. Education & Experience Dr. Dye holds a PhD in HEOR from the University of South Carolina, received his pharmacy training from The University of Texas at Austin, and is a registered pharmacist. He has experience conducting and leading HEOR for the American Cancer Society, Children’s Healthcare of Atlanta, Mercer University College of Pharmacy, Humana, UCB, Amgen, and now Ontada.

Lisa Herms, M.Sc. Sr. Observational Researcher

Expertise An international HEOR professional with proven experience leading and overseeing RWE studies in collaboration with pharmaceutical industry and academic partners, Ms. Herms has a special interest in the growing use of RWE, including development and validation of novel research methodologies, within oncology, as well as the dissemination of RWE findings for research and regulatory purposes. Education & Experience Ms. Herms holds a Masters in International Health Economics/Health Policy from the London School of Economics and Political Science and is pursuing a PhD in Economics (currently ABD) at American University, focusing on applied microeconomics and health economics. In previous roles, she has led healthcare market research functions. She also has extensive experience designing and leading RWE and HEOR studies.

Kat Aguilar, M.P.H. Sr. Manager, Observational Research

Expertise A health data researcher who specializes in EHR-based studies. She has co-authored over 40 publications that have explored the intersection between technology and healthcare. Education & Experience Kat Aguilar has an MPH from UCLA. She has over 15 years of experience leading studies with large real-world datasets, most recently with Ontada and focused on oncology/hematology. Prior to Ontada, she was a research scientist with Cerner and supported clinical content development, research technology implementation and grant submissions.

Qiqiang (John) Bian, Ph.D. Sr. RWE Research Director

Expertise Dr. Bian is a RWE expert in research design, quality/outcome measurement, and statistical methodology with a strong peer-reviewed publication record. He has expertise in natural experiments for health policy analysis, with more than 20-years of hands-on experience in working with large datasets (e.g., SEER-Medicare linked data) and 15-years of experience in leading and overseeing oncology-related RWE/HEOR projects in collaboration with pharmaceutical industry, government, and academic partners. Education & Experience Dr. Bian received his PhD in Health Economics from the School of Public Health at University of North Carolina at Chapel Hill. He holds a Master in Statistics from North Carolina State University. Before joining Ontada, Dr. Bian held positions at American Cancer Society, U.S. Department of Veterans Affairs, and Medical University of South Carolina.

Qiqiang (John) Bian, Ph.D.

E. Susan Amirian, M.S.P.H., Ph.D.

Pooja Chopra, M.S.

Lisa Herms, M.Sc.

Joseph Dye, Ph.D., R.PH.

Thomas Wilson, Ph.D., Dr.P.H.

Kat Aguilar, M.P.H.

LET'S CONNECT

Pooja Chopra, M.S. Director, Real World Evidence and Data Science

LET'S CONNECT

Thomas Wilson, Ph.D., Dr.PH. Sr. Oncology RWE Research Director

Expertise Ms. Chopra has expertise in Health Economics and Outcomes Research (HEOR), Market Access and Commercial Strategy. A professional with over 11 years of experience leading and conducting real world evidence studies in collaboration with life sciences partners and academic affiliates, she specializes in designing and executing retrospective studies and employing advanced statistical techniques to address research needs. Ms. Chopra has a special interest in conceptualizing HEOR and commercial strategy, and has expertise in the rare disease and oncology space. Her work has been presented at several clinical and economic conferences and published in peer-reviewed journals. Education & Experience Ms. Chopra holds a Master’s degree in Health Economics and Outcomes Research from the University of Houston.